Nephrology

Review: SGLT2 Inhibitors as a Potential Treatment for Alport Syndrome

In this review, the authors discuss sodium-glucose co-transporter-2 (SGLT2) inhibitors as a potential treatment in Alport syndrome, a rare genetic disease characterized by kidney disease and ocular and auditory defects. There is no cure but therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression of end-stage kidney disease (ESKD)....